Breeze Holdings Acquisition Corp. shareholders have approved the business combination with YD Biopharma Limited.
The combined company will be named YD Bio Limited and will trade on Nasdaq under the ticker symbol 'YDES'.
The transaction is expected to close in the coming days, pending customary closing conditions.
Stockholder Approval
Stockholders voted in favor of the Business Combination by a significant majority, reflecting confidence in the strategic move.
Company Name and Ticker Symbol
Upon closing, the combined entity will operate as YD Bio Limited and trade under the symbol 'YDES' on Nasdaq.
Advisors Involved
Legal advisors for YD Biopharma include ArentFox Schiff LLP, while Breeze is advised by I-Bankers Securities, Inc. and Woolery & Co. PLLC.
- The approval of the Business Combination signifies a pivotal moment for Breeze Holdings Acquisition Corp. and YD Biopharma Limited, paving the way for a strengthened presence in the biopharmaceutical sector.
- Trading on Nasdaq under the new ticker symbol 'YDES' will enhance visibility and access to capital markets for the combined company.
The successful approval of the business combination marks a significant milestone for both companies, setting the stage for future growth and collaboration in the biopharmaceutical industry.